Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 3CNS 1

Conditions

Breast Neoplasms 2352Neoplasms 1707Prostatic Neoplasms 1197Lung Neoplasms 923Colorectal Neoplasms 882Carcinoma, Non-Small-Cell Lung 867Leukemia, Myeloid, Acute 593Pancreatic Neoplasms 577Multiple Myeloma 549Carcinoma, Hepatocellular 516Brain Neoplasms 513Neoplasm Metastasis 459Head and Neck Neoplasms 454Melanoma 414Ovarian Neoplasms 413Glioblastoma 402Precursor Cell Lymphoblastic Leukemia-Lymphoma 400Stomach Neoplasms 375Uterine Cervical Neoplasms 365Squamous Cell Carcinoma of Head and Neck 361Rectal Neoplasms 341Recurrence 336Sarcoma 325Hematologic Neoplasms 323Colonic Neoplasms 323Lymphoma 319Triple Negative Breast Neoplasms 291Carcinoma, Renal Cell 283Urinary Bladder Neoplasms 281Glioma 278

Interventions

pertuzumab 1atezolizumab 1Trastuzumab 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × HER2-positive Metastatic Breast Cancer × 1 year × Clear all
NCT06595563 2026-05-07

ZEPHIR-02

Jules Bordet Institute

Phase 2 Recruiting
87 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

NCT06551116 2026-04-07

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Abramson Cancer Center at Penn Medicine

Recruiting
200 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡